Khiron Expands Product Offering in UK and Increases Patient Access – Yahoo Finance

  • After successful medical cannabis launching in Germany, Khiron 1/14, a high CBD flower is expected to be accessible Q2/21 for UK patients

  • Khiron intends to present further cannabis-based medical products using its registered breeds, recently exported from Colombia to Europe

  • Supply chain improvements Increase Access to medical cannabis for individuals in the United Kingdom

TORONTO, April 7, 2021 /PRNewswire/ – Khiron Life Sciences Corp. (“Khiron” or the”Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America along with Europe, is very happy to offer an operational update with regards to its source of EU-GMP medical cannabis products to the United Kingdom. To help alleviate bottlenecks and stock appointments, the business has generated an offshore stock of dried flower, for the express purpose of serving UK patients.

Khiron UK medical cannabis products CBD (CNW Group/Khiron Life Sciences Corp.)

Khiron UK medical cannabis products CBD (CNW Group/Khiron Life Sciences Corp.)

In addition, the business is broadening its product portfolio by introducing Khiron 1/14, a high-CBD flower to the UK in Q2/21. This follows a successful launching in Germany, in which it is prescribed for signs like anxiety, substance use disorder, and migraines. Khiron 1/14 will complement Khiron 20/1, a high-THC flower, which is currently being prescribed to individuals in the united kingdom. Prescribing experts will also be able to prescribe smaller amounts of their flower products in five – g jars (pictured below), thanks to enhanced capabilities at the provider’s EU-GMP certified satisfaction partner.

Tejinder Virk, President of Khiron Europe, remarked,”The European economy is now growing and Khiron is nicely placed through our distinguished schooling stage, mounting clinical signs, and EU-GMP certified products prepared for prescription. Our team continues to work diligently to increase patient access to medical cannabis products, and individuals may now gain through greater product selection and amounts. In the coming months, we intend to present further cannabis-based medical products from our registered Colombian breeds, elevating the degree of clinical information available to medical professionals in the united kingdom.”

Around Khiron Life Sciences Corp..

Khiron is a vertically integrated medical and CPG cannabis firm with core operations in Latin America, and operational action in Europe along with North America. Khiron is your major medical cannabis provider in Colombia along with the first firm accredited in Colombia for its cultivation, manufacturing, national supply and revenue, and international export of the low and high THC medical cannabis products. The Business has packed medical cannabis prescriptions in Colombia, Peru, Germany along with the United Kingdom, also is positioned to commence revenue in Mexico along with Brazil in 2021.

Leveraging wholly-owned medical clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product creation, and agricultural infrastructure to drive prescriptions and brand loyalty. Its Wellbeing unit established the first branded CBD skincare brand in Colombia, together with KuidaTM currently marketed in many jurisdictions in Latin America, the US along with United Kingdom. The Business is headed by Co-founder and Chief Executive Officer, Alvaro Torres, with a seasoned and diverse executive staff and Board of Directors.

Stop by Khiron online at and around Instagram @khironlife.

Cautionary Notes

Forward-Looking Statements

This media release may include certain”forward-looking information” along with also”forward-looking statements” within the meaning of applicable securities legislation. All information included herein that isn’t historical in nature may constitute forward-looking information. Khiron undertakes no duty to comment on analyses, statements or expectations made from third-parties in respect of Khiron, its own securities, or financial or operating results (as relevant ). Though Khiron considers that the expectations reflected in forward-looking statements in this press release are reasonable, these forward-looking statement was predicated on expectations, assumptions and factors regarding future events that might prove to be inaccurate and are subject to many risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or duty, except as required by law, to update or revise some forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its own Regulation Services Provider (as the term is defined in the policies of the TSXV) takes responsibility for the adequacy or accuracy of the press release.

Investor Contact:
Paola Ricardo
T: +1 -LRB-647-RRB- 556-5750

Media Contact:

Khiron Europe:
Tejinder Virk
Europe President

Khiron UK medical cannabis products THC (CNW Group/Khiron Life Sciences Corp.)

Khiron UK medical cannabis products THC (CNW Group/Khiron Life Sciences Corp.)

Khiron Life Sciences Corp (CNW Group/Khiron Life Sciences Corp.)



View first content to get multimedia:

SOURCE Khiron Life Sciences Corp..


Leave a Reply